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ABSTRACT
◥
Purpose: Non–small cell lung cancer (NSCLC) is a fatal disease
with poor prognosis. Amembrane-bound formofHsp70 (mHsp70)
which is selectively expressed on high-risk tumors serves as a target
for mHsp70-targeting natural killer (NK) cells. Patients with
advanced mHsp70-positive NSCLC may therefore benefit from a
therapeutic intervention involving mHsp70-targeting NK cells. The
randomized phase II clinical trial (EudraCT2008-002130-30)
explores tolerability and efficacy of ex vivo–activated NK cells in
patients with NSCLC after radiochemotherapy (RCT).
Patients and Methods: Patients with unresectable, mHsp70-
positive NSCLC (stage IIIa/b) received 4 cycles of autologous NK
cells activated ex vivo with TKD/IL2 [interventional arm (INT)]
after RCT (60–70Gy, platinum-based chemotherapy) or RCT alone
[control arm (CTRL)]. The primary objective was progression-free
survival (PFS), and secondary objectives were the assessment of
quality of life (QoL, QLQ-LC13), toxicity, and immunobiological
responses.
Results:The NK-cell therapy after RCT was well tolerated, and
no differences in QoL parameters between the two study arms
were detected. Estimated 1-year probabilities for PFS were 67%
[95% confidence interval (CI), 19%–90%] for the INT arm and
33% (95% CI, 5%–68%) for the CTRL arm (P ¼ 0.36, 1-sided log-
rank test). Clinical responses in the INT group were associated
with an increase in the prevalence of activated NK cells in their
peripheral blood.
Conclusions: Ex vivo TKD/IL2-activated, autologous NK cells
are well tolerated and deliver positive clinical responses in patients
with advanced NSCLC after RCT.
Introduction
Lung cancer remains a major health burden with a mortality
rate of almost 1.6 million deaths worldwide per year (1). Despite
aggressive, combined treatment regimens consisting of simulta-
neous radiotherapy (up to 70 Gy) and platinum-based chemother-
apy, tumor control and overall survival (OS) in patients with
unresectable, advanced non–small cell lung cancer (NSCLC) remain
poor with an OS of less than 2 years (1–5). We have previously
reported that the stress-inducible Hsp70, which is frequently over-
expressed in many malignant tumor types, including advanced
NSCLC, is selectively presented on the cell surface of many tumor,
but not normal, cells and therefore serves as a tumor-specific
target (6). We have also demonstrated that the expression
density of a membrane-bound form of Hsp70 (mHsp70) is further
increased by radio- and/or chemotherapy and hyperthermia (7–10);
that it is more highly expressed on aggressive and metastatic
diseases (11); and, importantly, that it is recognized by NK cells
that have been prestimulated with an Hsp70-derived peptide
(“TKD”; TKDNNLLGRFELSG, aa 450–463) and low-dose IL2
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(100 IU/mL, TKD/IL2; ref. 12). Therefore, we propose that patients
with advanced mHsp70-positive NSCLC will benefit from a ther-
apeutic intervention involving mHsp70-targeting NK cells. Of
relevance is the fact that feasibility and safety of an adoptive
transfer of ex vivo–stimulated, autologous NK cells have already been
demonstrated in a phase I clinical trial involving 12 patients with
metastatic colorectal cancer andNSCLC (13) receiving up to 6 NK-cell
reinfusion cycles, and in a subsequent case study in which a patient
received up to 9 NK-cell reinfusion cycles (14). Herein, we report on
the outcome of a randomized, investigator-initiated phase II clinical
study which explored tolerability and efficacy of ex vivo–activated
autologous NK cells in patients with advanced stage NSCLC after
radiochemotherapy (RCT). The ex vivo stimulation of NK cells is a
prerequisite because it has been demonstrated for other tumor entities
that NK cells in patients with solid tumors are in a cytolytic inactive,
resting stage (15).
Materials and Methods
Patients, ethics, and inclusion and exclusion criteria
Sixteen patients [8 interventional arm (INT), 8 control arm
(CTRL)] with histologically proven, inoperable, clinical stage IIIa/b
squamous cell lung cancer (a subtype of NSCLC) were randomized
and analyzed in the phase II clinical trial (16). Approval for
the study was obtained by the Institutional Ethical Review Boards
of all participating clinical centers. Written informed consent
was obtained from all patients before start of therapy. A separate
approval by the Institutional Ethical Review Boards was given for
screening serum levels of Hsp70 and immunophenotyping of blood
lymphocytes in patients in the prestudy part of the trial at study
visits VS (Hsp70 screening) and V0 (after RCT). Inclusion and
exclusion criteria are summarized in Supplementary Table S1. The
study was conducted in accordance to ethical guidelines as deter-
mined by the Declaration of Helsinki.
Patient recruitment was difficult because immune checkpoint
inhibitor therapies were competing for the same patient collective at
the same time. After approval of durvalumab, all patients with NSCLC
in stage III were treated with immune checkpoint inhibitor therapy,
and the NK study had to be closed.
Prestudy part: Hsp70 screening
As shown in a CONSORT diagram, a total of 120 patients
were screened for their tumor mHsp70 status, as determined by
analyzing circulating levels of Hsp70 using the lipHsp70 ELISA (17).
Eighty-six patients (72%) were categorized as being mHsp70 positive.
Thirty patients were diagnosed as having stage IIIa/b disease; 56 were
in a metastasized tumor stage (IV), diagnosed as SCLC, or had an
adenocarcinoma histology; 3 patients declined participation; and 11
patients refused to get RCT (Fig. 1A, upper part).
Study treatment
Patients with mHsp70-positive tumors were staged regularly at
defined time intervals following standard RCT (60–70 Gy, platinum-
based chemotherapy) in the CTRL arm. In the INT arm, patients with
mHsp70-positive tumors received TKD/IL2-activated, autologous NK
cells (somatic cell therapy, plasma-derived medicinal product, IMP)
subsequent to standard RCT (60–70 Gy, platinum-based chemother-
apy). Patients with an insufficient leukapheresis product or a failure of
NK-cell activation (as defined by less than 3% of NK cells in the
lymphocyte population and/or less than 1.2-fold upregulation in the
intensity of CD94 expression on NK cells) were excluded from the
study. Tumor staging in both groups was performed using PET/CT or
CT scanning.
Leukapheresis, ex vivo stimulation of human NK cells with
TKD/IL-2 and reinfusion protocol
Within 1 to 2 months after completion of RCT, leukocyte
concentrates were obtained from patients by a 3- to 4-hour leuka-
pheresis (COBE Spectra Apheresis System) centrally at the Uni-
versity Hospital Regensburg, Germany. Peripheral blood lympho-
cytes (PBL) were isolated by density gradient centrifugation
in a closed SEPAX Cell Processing System (Biosafe) and resus-
pended in CellGro SCGM stem cell medium (CellGenix). After
counting, PBLs (5–10  106/mL in CellGro medium) were incu-
bated with 2 mg/mL GMP-grade TKD peptide (Bachem) and
100 IU/mL recombinant IL2 (Proleukin, Novartis) in 250 mL
Teflon bags (Vue-Life-118, CellGenix) under gentle rotation at
37C, 5% v/v CO2 in a humidified atmosphere (90%; Heraeus) for
3 to 5 days in a GMP-accredited laboratory (TUMCells). Treated
cells were harvested, washed twice, and resuspended in Ringer‘s
lactate solution (500 mL) containing 0.1% v/v human serum
albumin. Sterility testing of intermediate and final products was
performed before/after stimulation and before reinfusion. TKD/IL2,
autologous PBLs were reinfused into the patient by intravenous
injection over 30 to 60 minutes using a stem cell reinfusion set. The
time period between washing of the cells until reinfusion did not last
more than 24 hours. Patients were treated up to 4 times with
ex vivo–activated autologous NK cells every 2 to 6 weeks between
study visits V1 and V5.
Laboratory parameters and flow cytometric analysis of PBLs
Routine laboratory parameters (differential blood counts, RBC
parameters, and white blood cell counts) and blood chemistry
(creatinine, AST/SGOT, ALT/SGPT, g-GT, and LDH) were deter-
mined after each therapy (RCT, NK cells) and every 3 months in the
follow-up period.
Blood samples for effector cell phenotyping were taken at visits
VS (Hsp70 screening), V0 (after RCT), V1 (randomization), and
in the follow-up periods V5 (3–4 months after randomization), V6
(6–7 months after randomization), V7 (9–12 months after ran-
domization), and V8 (18 months after randomization, end of the
Translational Relevance
In this phase II trial, it was shown that progression-free survival
was improved in patients who received ex vivo Hsp70-stimulated
natural killer (NK) cells compared with patients receiving only
standard-of-care radiochemotherapy. Clinical responses of the
interventional (INT) group were associated with an increased
prevalence of activated mHsp70-targeting NK cells in the periph-
eral blood, and elevated extracellular Hsp70 levels were predictive
for therapy response. Together with promising data of a case study,
these findings provide the basis for future clinical approaches
consisting of radiochemotherapy and/or surgery, mHsp70-target-
ingNK cells, and immune checkpoint inhibition in the treatment of
patients with advanced non–small cell lung cancer. Because Hsp70
is not only present on the plasma membrane of lung tumors, but
also on a large variety of other tumor entities, the combined
immunotherapeutic approach might also exert beneficial effects
in patients with breast, colorectal, pancreas, and head and neck
cancers; glioblastoma; and hematologic diseases.
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study). The presence of the following lymphocyte subsets in the
peripheral blood of patients at the indicated study visits was
determined by multiparameter flow cytometry using a BD FACS-
Calibur flow cytometer (BD Biosciences): CD3/CD19þ B cells,
CD45þ/CD3þ T cells, CD3þ/CD4þ helper T cells, CD3þ/CD8þ
cytotoxic T cells, CD3þ/CD4þ/CD25þ/FoxP3þ regulatory T cells
(Treg), CD3þ/CD56þ NK-like T (NKT) cells, CD3þ/CD16þ NKT
cells, CD3þ/NKG2Dþ NKT cells, CD3þ/CD69þ NKT cells, CD3/
CD56þ NK cells, CD3/CD16þ NK cells, CD3/CD94þ NK cells,
CD3/NKG2DþNK cells, CD3/NKp30þNK cells, CD3/NKp46þ
NK cells, and CD3/CD69þ NK cells. The antibody combinations
used for the study have been described previously (18).
Determination of serum Hsp70 levels
Blood samples (7.5 mL) were collected in EDTA KE separator
tubes (S-Monovette Z, Sarstedt) at diagnosis (VS), after RCT (V1),
and 3 to 4 months after randomization (V5). EDTA blood was
centrifuged at 1,500 g for 15 minutes. For serum separation,
blood was allowed to clot for 15 minutes at room temperature
and then centrifuged at 750 g for 10 minutes. Aliquots of plasma/
serum (100–300 mL) were stored at 80C until further analysis.
Hsp70 concentrations were determined using the lipHsp70
ELISA which detects both exosomal and free Hsp70 in serum/
plasma (17).
Statistical methods
Sample size calculation
Sample size calculations were based on the following. Previous
studies have reported progression-free survival (PFS) probability
after 18 months for a combined sample of unselected (mHsp70-
positive and -negative) patients with NSCLC that had survived
without tumor progression for at least 5 months after the start of
RCT to be approximately 0.30 (3, 4) without immune checkpoint
inhibitors (19). The probability for PFS for patients with more
highly aggressive mHsp70-positive tumors for stable disease at
the end of RCT was assumed to be 0.20 and that the 18-month
Figure 1.
A, CONSORT diagram and schematic representation of the clinical course and interventions of the randomized phase II clinical trial. NK-cell treatment cycles 1
to 4 are marked in green. Visits for blood donations and timelines (months) are indicated at the bottom. B, Kaplan–Meier curves for PFS of patients of the INT
(solid line) and CTRL (dotted line) arms of all analyzed patients. C, Representative CT and PET-CT scans (axial soft-tissue window) of patients of the INT arm
with complete response (CR), partial response (PR), and progressive disease (PD) before and after therapies: screening for mHsp70 (VS), 1–2 months after
RCT at randomization (V1), last follow-up 18 months after randomization (V8). (Continued on the following page.)
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PFS probability would improve to at least 0.45, translating to an HR
of 0.50.
Analysis sets
The intention to treat (ITT) group consists of all randomized
subjects who received at least one study medication. The per protocol
population consists of all ITT patients without major protocol viola-
tions, as defined during the Blinded Data Review Meeting. The safety
population consists of all randomized subjects with any postrando-
mization data. All efficacy analyses were performed “as randomized”
on the ITT population and “as treated” on the per protocol popula-
tions. The ITT population was the primary analysis population. All
safety analyses were based on the safety population. Safety analysis was
performed “as treated.”
Efficacy analyses
PFSbetweenbothstudygroupswascomparedusinga log-rank teston
a 1-sided level of significance of a ¼ 5%. Estimated 1-year PFS
probabilities and median PFS times are reported with 95% confidence
intervals (95% CI). A Cox regression model was fitted to the data in
order to estimate the HR (with 95% CI) between the study groups. Due
to the small sample size, no subgroup analyses were performed.
Analysis of theprimary endpointwas alsoperformedontheperprotocol
set. Secondary analyses were performed in an explorative manner.
Figure 1.
(Continued. ) D, Comparison of the proportion of different lymphocyte subpopulations in responders and nonresponders of the INT and CTRL arm at visits
VS (screening), V0 (after RCT), V1 (1–2 months after RCT at randomization), V5 (3–4 months after randomization), V6 (6–7 months after randomization),
V7 (9–12 months after randomization), and V8 (18 months after randomization). Lymphocyte subpopulations were assessed using the following
antibody combinations: CD3/CD19þ B cells; CD3þ/CD45þ T cells; CD3þ/CD4þ T helper cells; CD3þ/CD8þ cytotoxic T cells; CD3þ/CD16þ, CD3þ/CD56þ,
CD3þ/NKG2Dþ NK-like T cells (NKT); CD3/CD16þ, CD3/CD56þ, CD3/CD94þ, CD3/NKG2Dþ, CD3/NKp30þ, CD3/CD46þ, CD3/CD69þ NK cells.
Responders of the INT arm, n ¼ 4; nonresponders of the INT arm, n ¼ 2; responders of the CTRL arm, n ¼ 2; nonresponders of the CTRL arm, n ¼ 5. , P ≤ 0.05.
(Continued on the following page.)
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Distributions of the sum score of the QLQ-C30 questionnaire
are depicted by boxplots, with mean values and standard deviations
being presented for both groups. Mean values between study
groups at relevant timepoints were compared using two-sample t
tests. The response category according to immune-related response
criteria (irRC) and RECIST1.1 at the last available assessment of
each patient was determined and used to describe the tumor
response. Distribution of response categories for both study groups
is given.
Safety analyses
Adverse events (AE) and severe AEs (SAE)were classified according
to CTCAEV.V4.0 and coded according to MedDRAV17.0 English.
Frequencies of observed AE and SAE are presented by System
Organ Class and Preferred Term in both study groups. For assessing
toxicity, the maximum observed AE intensity was derived for each
included patient. Proportions of patients with at least one AE of
grade 3 or higher (defined as a toxic event) were compared using the
Fisher exact test. Frequencies of performed apheresis and successful
reinfusions are provided for each patient allocated to the INT group.
Distributions of increases in the density of CD94 expression on NK
cells, a surrogate marker for confirming NK-cell activation and their
reactivity against mHsp70-positive tumors, are presented as the
mean, standard deviation, minimum, and maximum for each
treatment cycle.
Results
Study treatment
The clinical course, therapeutic interventions, study visits, and
time scale of patients of the INT arm are provided in Fig. 1A (lower
part). After screening (VS), patients with mHsp70-positive, non-
resectable NSCLC stage IIIa/b received standard first-line simulta-
neous platinum-based RCT (60–70 Gy; V0). An mHsp70-positive
tumor phenotype was confirmed by elevated exosomal Hsp70
serum levels (above a threshold of 7.4 ng/mL), as determined by
the lipHsp70 ELISA (17). mHsp70 could not be determined on
tumor cells because it was not allowed to get biopsies due to ethical
restrictions.
Patients who completed RCT without progression according to
routine CT were randomized into the trial within 1 to 2 months
after RCT (V1). Patients of the INT arm were treated up to 4 times
with ex vivo TKD/IL2-activated, autologous NK cells as a somatic
cell therapy (plasma-derived medicinal product, IMP) every 2 to
6 weeks subsequent to RCT. Patient characteristics (Table 1A)
and the absolute numbers of reinfused PBLs and CD3/CD56þ NK
Figure 1.
(Continued. ) E, Representative dot blot analysis
of responders of the INT versus CTRL arms at V1
(1–2 months after RCT at randomization), V5 (3–
4 months after randomization), V6 (6–7 months
after randomization), and V8 (18 months
after randomization). The following lymphocyte
subpopulations are shown in the different quad-
rants: CD3þ/CD4þ T helper cells; CD3þ/CD8þ
cytotoxic T cells; CD3þ/CD16þ, CD3þ/CD56þ,
CD3þ/NKG2Dþ, CD3þ/CD69þ NK-like T cells
(NKT); and CD3/CD16þ, CD3/CD56þ, CD3/
CD94þ, CD3/NKG2Dþ, CD3/NKp30þ, CD3/
CD46þ, CD3/CD69þ NK cells. The proportions of
all lymphocyte subsets are shown in black, and
the proportions of CD3 NK cells are shown in
green. The CD4/CD8 ratios and the fold increase in
CD3/CD56þ, CD3/CD94þ, and CD3/NKG2Dþ
NK-cell subsets at V5, V6, and V8 compared
with V1 are shown below the dot blot graphs.
(Continued on the following page.)
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cells, as well as the proportion of NK cells are shown in Table 1B.
Overall, the number of reinfused NK cells ranging from 1.04  108
(minimum) to 5.63  108 (maximum) increased between the
first and third reinfusion cycles and remained elevated after
the fourth cycle (Table 1B). The proportion of CD3/CD56þ
NK cells in the leukapheresis products ranged between 6% and
23%. Peripheral blood was taken at study visits VS, V0, V1, V5, V6,
V7, and V8.
Patient demographics and disposition
The median age of the patients was 63 years (range, 56–76 years).
One patient of the CTRL arm was randomized, but no further data
were collected. Of the 8 patients allocated to the INT arm, 2 were
excluded from the study prior to first administration of the study
medication due to medical conditions (SAE: pneumonia, pyrexia)
which were identified before the first intended treatment cycle.
These patients were considered in the description of the study
population and for assessment of safety, but were excluded from the
efficacy analyses. Of the 6 remaining patients, 5 completed all 4 NK-
cell treatment cycles and 1 patient received only one NK-cell
transfer. Although leukapheresis was performed 3 times, reinfusion
was possible only once because the upregulation of the CD94
expression on NK cells (as a potency marker) failed the criteria
twice (01 103; Table 1B).
Quality-of-life (QoL-C30)
Results for the sum score of the QLQ-C30 questionnaire of
the INT and CTRL group are presented as means, standard devia-
tions, differences in means (95% CI), numbers of eligible ques-
tionnaires, and P values for both study groups for visits 1, 6, 7, 8,
Figure 1.
(Continued. ) F, Comparison of the proportion of NK-cell subsets in responders and nonresponders of the INT versus CTRL group at visits VS (screening),
V0 (after RCT), V1 (1–2 months after randomization), V5 (3–4 months after randomization), V6 (6–7 months after randomization), V7 (9–12 months
after randomization), and V8 (18 months after randomization). The following NK-cell subsets were assessed: CD3/CD16þ, CD3/CD56þ, CD3/CD94þ, CD3/
NKG2Dþ, CD3/NKp30þ, CD3/CD46þ, CD3/CD69þ. Responders of the INT arm, n ¼ 4; nonresponders of the INT arm, n ¼ 2; responders of the CTRL
arm, n ¼ 2; nonresponders of the CTRL arm, n ¼ 5.  , P ≤ 0.05. G, Schematic representation of the distribution of NK cells (green) and CD8þ cytotoxic T cells
in nonresponders and responders of the INT and CTRL arms.
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and 9 (Table 1C). No statistically significant differences were
observed between both study groups.
Toxicities/adverse events
A toxic event was defined as an AE of grade 3 or higher according
to NCI CTCEv4.0. Overall, 8 AEs (all grade 3) were documented in
4 different patients and deemed unrelated to the study medication, 6
in the INT group (3 patients) and 2 in the CTRL group (1 patient).
A total of 40 AEs were reported in 10 patients, who experienced at
least one AE, 2 in the CTRL group, and 3 in the INT group
(Supplementary Table S2). No SAE was related to the IMP, and
no suspected unexpected serious adverse reactions (SUSAR) were
reported in the study. Five protocol violations in 4 patients, who
were excluded from the per protocol set, were rated as major (i.e., no
laboratory samples taken at screening visit, no reinfusion of blood
due to failed activation of NK cells—twice in 1 patient). No patient
died between randomization and the final tumor assessment which
was undertaken 18 months after randomization (V8).
Routine laboratory parameters, such as differential blood cell
counts, hemoglobin concentration, RBC parameters, PLT and WBC
counts, AST/SGOT, ALT/SGPT, g-GT, LDH, and sodium, remained
within normal ranges throughout the therapeutic interventions and in
the follow-up period in all patients (data not shown). However, 2
patients of the INT group showed increased blood creatinine levels,
and decreased blood potassium levels were observed in 1 patient in the
CTRL group. Side effects of the leukapheresis were minimal and most
likely not related to the NK-cell therapy.
Responses
A total of 16 patients (7 females and 9 males) with firstly diagnosed
histologically proven,mHsp70-positiveNSCLC (8 patients stage IIIa, 8
patients stage IIIb) who were at least progression-free after RCT were
randomized into the CTRL (8 patients) and the INT (8 patients) arms
of the phase II clinical trial between November 2014 and August 2017.
Tumor assessments according to RECIST1.1 (RC1.1) and irRC were
conducted 1 to 2 months after RCT when radiation-induced pneu-
monitis starts to decrease, in both groups following clinical routine CT
in the follow-up period 3–4 (V5), 6–7 (V6), 9–12 (V7), and 18 (V8)
months after randomization. Tumor progression was observed in 2
patients of the INT arm, one of them receiving only 1 NK-cell cycle,
and 5 patients in the CTRL arm. Kaplan–Meier curves for PFS
are shown in Fig. 1B. Estimated 1-year probabilities for PFS are
67% (95% CI, 19%–90%) for the INT group and 33% (95% CI,
5%–68%) for the CTRL group (P ¼ 0.36, one-sided log-rank test).
The estimated HR between both groups was 0.77 (95% CI, 0.17–3.45,
Cox regression). In the per protocol population, estimated 1-year
survival probabilities were 80% (95% CI, 20%–97%) in the INT
group and 25% (95% CI, 1%–67%) in the CTRL group (HR, 0.43;
95% CI, 0.07–2.63).
At the last documented visit, 1 patient of the INT group had an
immune-related complete response (irCR), 1 patient had a partial
response (irPR), 2 patients had stable disease (irSD), and 2 patients had
progressive disease (irPD) at V6 and V7 (Table 1D). In the CTRL
group (Table 1E), 1 patient had an irPR, 1 patient had irSD until V6,
and 5 patients had irPD. One patient of the CTRL group was a drop-
out before V3. Due to the fixed end of the study at 18 months after
randomization, no further follow-up data are available.
In total, 7 patients showed PD. According to RECIST1.1 in the INT
arm, 2 patients had new lesions subcarinal and in the lymph node (LN)
and a nontarget lesion (NTL;Table 1D). In the CTRL group, 2 patients
had new lesions (NL) in the lymph node and mediastinum, 1 patient
had a target lesion (TL) and intrapulmonarymetastasis (TLþNL), and
2 patients had target lesions in the lung (Fig. 1E). Representative CT
and PET-CT images of patients (INT arm) who showed either CR, PR,
Table 1B. Number of reinfused peripheral lymphocytes (PBL), CD3/CD56þNK cells at the different reinfusion cycles of the INT group.
Reinfusion cycle 1 2 3 4
# PBL NK PBL NK PBL NK PBL NK
CD3/CD56þ 109 x108 x109 x108 x109 x108 x109 x108
01 103 0.69 0.26 0.18 0.31 0.18 1.23 — —
CD3/CD56þ No infusion 4% No infusion 6% 7%
02 201 1.21 1.04 1.35 1.95 1.21 2.06 1.16 2.02
CD3/CD56þ 13% 12% 14% 15%
02 202 1.67 2.33 1.26 1.38 1.44 2.17 2.23 3.64
CD3/CD56þ 14% 13% 14% 16%
03 303 1.21 1.7 2.5 3.5 3.5 5.3 2.9 4.0
CD3/CD56þ 10% 14% 15% 16%
05 501 1.35 1.11 3.21 4.27 2.14 2.04 2.6 2.72
CD3/CD56þ 6% 10% 11% 13%
05 504 5.7 4.2 5.4 5.28 4.9 5.63 3.5 4.32
CD3/CD56þ 21% 22% 21% 23%
Note: Viability of the reinfused cells was always >90%. Leukapheresis products 1 and 2 of patient 01 103 were not reinfused because the upregulation of the CD94
expression as a potency marker failed the criteria.
Table 1A Patient characteristics.
Patient characteristics N ¼ 16
Gender
Male 9
Female 7
Age 56–76 years (mean 63 years)
Histology squamous NSCLC 16
Stage
IIIa 8
IIIb 8
Recruitment
INT arm 8 (drop-out 2)
CTRL arm 8 (drop-out 1)
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or PD are shown in Fig. 1C. In the top plot, a mediastinal lymph
node and a tumor in the left hilum which are classified as target
lesions are clearly visible at VS. Both lesions are not visible in the
following examinations at V1 after RCT and V8, 18 months after
randomization, resulting in a CR. In the middle plot, a large tumor
mass in the right lung is visible at VS. Obviously, this mass showed a
drastic shrinkage in the follow-up period at V8, although a small
residuum is still visible, resulting in a PR. In the bottom plot, a
lymph node in the right hilum is visible at VS. Due to a new lesion
which appeared in the follow-up period at V8, a PD was diagnosed
in this patient.
Overall, plasma/serum Hsp70 levels at diagnosis (VS, 11.2  3.4
ng/mL) were above those of healthy individuals (>7.4 ng/mL) in
all patients. At randomization (V1, 1–2 months after RCT) and 3
to 4 months after randomization (V5), Hsp70 plasma/serum
levels dropped to 10.2  3.8 and 10.6  5.2 ng/mL, respectively.
A separate comparison of responders and nonresponders of the INT
as well as the CTRL group revealed an increase in the Hsp70 values
after RCT (V1) followed by a drop below initial levels at V5 in
responders, whereas in nonresponders, Hsp70 levels dropped after
RCT, but increased at V5 (Table 1F).
B, T, NKT, andNK-cell subsets in responders and nonresponders
in the INT and CTRL groups
The composition of major lymphocyte subpopulations of all study
patients was determined at the following visits: screening for
mHsp70 (VS), after RCT (V0), 1–2 months after RCT at random-
ization (V1), 3–4 months after randomization (V5), 6–7 months
after randomization (V6), 9–12 months after randomization (V7),
and 18 months after randomization (V8).
Proportions of CD3/CD19þ B cells, CD3þ/CD45þ T cells,
CD3þ/CD4þ T helper cells, and CD3þ/CD8þ cytotoxic T cells
between VS and V8 in responders (CR, SD, PR; n ¼ 4) and
nonresponders (PD; n ¼ 2) in the INT group did not differ
significantly (Fig. 1D, left plot). With respect to CD3þ/CD4þ/
CD25þ/FoxP3þ Tregs, nonresponders compared with responders
showed elevated mean ratios at V1 (4.9% vs. 1.6%) and V7 (5.6% vs.
2.1%). In line with healthy individuals, the percentage of CD4þ T
cells was always above that of CD8þ cytotoxic T cells throughout
the entire clinical course (VS–V8) with CD4/CD8 ratios ranging
between 4.4 and 3.5. With respect to major NKT subpopulations
such as CD3þ/CD16þ, CD3þ/CD56þ, and CD3þ/NKG2Dþ cells,
no significant differences were observed in responders and non-
responders of the INT arm (Fig. 1D, left plot).
Similar to the INT group, no major differences in the proportion of
CD3/CD19þ B cells, CD3þ/CD45þ T cells, CD3þ/CD4þ T helper
and CD3þ/CD8þ cytotoxic T cells, and CD3þ/CD4þ/CD25þ/FoxP3þ
Tregs were observed in responders (SD, PR; n¼ 2) and nonresponders
(PD; n ¼ 5) of the CTRL group (Fig. 1D, right plot). However,
decreased CD4/CD8 ratios ranging between 0.22 and 0.78 between
V1 and V8 were observed in responders of the CTRL group (Fig. 1E).
Significantly increased proportions of CD3þ/CD16þ NKT cells were
observed between V5 and V7, whereas that of CD3þ/NKG2Dþ NKT
cells were found to be decreased in responders of the CTRL group
(Fig. 1D, right plot).
The most striking differences were observed in the NK-cell
subsets of the INT and CTRL groups. Overall, the percentage of
CD3/CD16þ, CD3/CD56þ, CD3/CD94þ, CD3/NKG2Dþ,
CD3/NKp30þ, CD3/NKp46þ, and activated CD3/CD69þ NK
cells in responders of the INT group was always above that of
Table 1D. Tumor assessment in the INT group (INT, n ¼ 6) and localization of lesions at PD.
INT (NK cycles) irRC Visit RC1.1 Visit Localization of lesions Date PFS months
01 103 (1) irPD V6 PD V6 NL subcarinal 11/2016 4
02 201 (4) irCR >V8 CR >V8 9/2016 15
02 202 (4) irSD V8 SD V8 6/2016 9
03 303 (4) irSD >V8 SD >V8 7/2017 16
05 501 (4) irPD V6 PD V7 NTLþNL LN 5/2015 6.5
05 504 (4) irPR V8 SD V8 5/2018 11
Abbreviations: LN, lymph node; NL, new lesion; NTL, nontarget lesion; RC1.1, RECIST 1.1.
Table 1C. Summary of the QLQ-C30 sum score for both study groups at different visits.
Visit Group N Mean
Standard
deviation Diff in means (95% CI) P value
1 INT 7 67.4 16.7 6.8 0.547
CTRL 6 74.2 21.5 (31.1 to 17.5)
6 INT 3 92.5 4.1 9.9 0.140
CTRL 7 82.6 14.6 (4.1 to 23.9)
7 INT 6 87.0 6.2 12.0 0.188
CTRL 6 75.0 18.8 (7.7 to 31.8)
8 INT 5 77.8 19.6 5.2 0.734
CTRL 5 72.6 26.3 (29.1 to 39.5)
9 INT 2 84.5 9.8 6.0 0.687
CTRL 3 78.4 20.3 (37.8 to 49.9)
Note: Presented are the number of available questionnaires for each study group (N), mean values, standard deviations, differences in means between study groups
with 95% CI, and the P value of the two-sided t test comparing group means.
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nonresponders until V8 (Fig. 1D, left plot). In stark contrast to
the INT group, significantly lower NK-cell counts at V5 were
observed in responders of the CTRL group (who did not receive
adoptive NK-cell transfer; Fig. 1D, right plot). After V5 the
proportion of NK cells in the CTRL arm dropped until V8, whereas
that of the INT arm remained to be elevated. Therefore, we
speculate that the increased ratios of NK cells in the responders
of the INT arm are most likely related to the adoptive transfer of the
ex vivo–stimulated NK cells. An increased proportion of CD3/
CD69þ NK cells documents the activation status of the NK cells
after V5. A comparison of the ratios of immune cell subsets in
responders versus nonresponders revealed a drop in all NK-cell
subpopulations in nonresponders at PD in the INT arm, but not in
the CTRL arm (Supplementary Table S3).
CD4/CD8 T cells, NKT, and NK-cell subsets in responders of the
INT and CTRL arms
CD4/CD8 ratios of a representative responder of the INT and
CTRL arms indicate values ranging from 3.5 to 4.4 and 0.22 to
0.78, respectively (Fig. 1E). The percentage of all major NKT subsets
such as CD3þ/CD16þ, CD3þ/CD56þ, CD3þ/CD94þ, CD3þ/
NKG2Dþ, and CD3þ/CD69þ cells remained stably low between V1
and V8 in the INT arm, whereas, in the CTRL arm, the percentages of
CD3þ/CD16þ, CD3þ/NKG2Dþ, and CD3þ/CD69þ NKT cells were
elevated in responders.
Between randomization (V1), NK-cell therapy (V5), and in
the follow-up period 6–7 (V6) and 18 months (V8) after random-
ization, a massive upregulation in CD3/CD16þ (V6, 4x; V8, 4x),
CD3/CD56þ (V5, 8.6x; V8, 9x), CD3/CD94þ (V5, 1.8x; V8 4.2x),
and CD3/NKG2Dþ (V5, 3.6x; V8, 3.3x) NK-cell subsets was
observed in responders of the INT arm (Fig. 1E). In contrast, levels
of CD3/CD56þ, CD3/CD94þ, and CD3/NKG2Dþ NK-cell
subsets remained at low levels (1% to 6%) between V1 and V8 in
responders of the CTRL group (Fig. 1E).
NK-cell subsets in responders and nonresponders of the INT and
CTRL arms
A comparison of all tested NK-cell subsets in responders and
nonresponders of the INT and CTRL arms throughout the entire
clinical course (VS–V8) revealed significantly higher proportions of
CD3/CD16þ, CD3/CD56þ, CD3/CD94þ, CD3/NKG2Dþ,
CD3/NKp30þ, and CD3/NKp46þ NK cells in responders of the
INT group than in responders of the CTRL arm at V8 (Fig. 1F). Lower
proportions of NK cells were present in nonresponders of the INT arm
compared with nonresponders of the CTRL arm between VS and V5
(first follow-up after 3–4months). BetweenV5 andV8 in the follow-up
period (6–18 months after randomization), the percentages of all
NK-cell subsets (apart from CD3/CD16þ NK cells) dropped in all
nonresponders of the INT and CTRL arms.
Overall, the PFS of patients who receivedNK-cell therapy (INT)was
improved compared with that of patients who only received RCT
(CTRL), and it was apparent that clinical responses in the INT group
were associated with an increase in the prevalence of activatedNK cells
(Fig. 1G).
Discussion
Patients with NSCLC are typically treated with combined regi-
mens such as RCT, targeted therapies, and/or immune therapies
such as those that employ monoclonal antibodies to target the
programmed cell death protein-1 (PD-1) on CD8þ T lymphocytes
and NK cells, or their ligand, PD-L1, on cancer cells—so-called
“checkpoint inhibitors.” Although the introduction of immune
checkpoint blockade has improved clinical outcomes (19–21), a
relevant proportion of patients do not adequately respond to this
therapy due to immunosuppressive mechanisms driven by hypoxia
and other factors in the tumor microenvironment (22), the absence
of antitumor-specific effector cells, immune escape mechan-
isms (23), and other, as yet, unidentified reasons.
A global profiling of cell surface antigen expression and flow
cytometric analysis using an Hsp70-specific mAb (cmHsp70.1) or a
Fab fragment derived thereof (6, 24) has identifiedmHsp70 as a tumor-
specific target. Depending on its subcellular distribution and expres-
sion density, Hsp70 fulfills different prosurvival functions (25). On the
one hand, high cytosolic Hsp70 levels can impede apoptotic pathways
in tumor cells (25), and elevated mHsp70 expression densities are
associated with resistance to radiotherapy (26). On the other hand,
mHsp70 has been identified as a trigger to activate NK cells in the
presence of IL2, and a high mHsp70 density supports the capacity of
Hsp70-activated NK cells to kill tumor cells (1, 6, 20, 27, 28). NK cells
Table 1F. Hsp70 plasma/serum levels in responder and
nonresponder patients of the INT and CTRL arms at visits VS, V1,
and V5.
Hsp70 VS (ng/mL) V1 V5
INT
Responder 13.65.2 15.07.2 11.16.1
Nonresponder 10.30.7 5.60.5 9.53.0
CTRL
Responder 11.83.1 12.80.9 8.06.0
Nonresponder 9.24.5 7.46.7 13.75.8
All patients 11.23.4 10.23.8 10.65.2
Note: VS, screening for Hsp70; V1, randomization 1–2 months after RCT; V5, 3–4
months after randomization.
Table 1E. Tumor assessment in the control group (CTRL, n ¼ 7) and localization of lesions at PD.
CTRL irRC Visit RC1.1 Visit Localization of lesions Date PFS
01 101 irPD V7 PD V7 TL lung 9/2015 6
01 102 irPD V6 PD V6 NL LN 10/2016 3
02 203 irSD V6 SD V6 5/2016 2
03 301 irPD V6 PD V6 TL lung 4/2015 1
03 302 irPD >V8 PD >V8 TLþNL intrapul mets 10/2016 19
05 502 irPD >V8 PD >V8 NL mediastinum 2/2018 15
05 503 irPR >V8 PR >V8 4/2018 14
Abbreviations: Intrapul mets, intrapulmonary metastasis; LN, lymph node; NL, new lesion; RC1.1, RECIST 1.1; TL, target lesion.
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play a crucial role in the first-line defense against cancer (29–32).
Studies have indicated that the OS of patients with oropharyngeal
cancer positively correlates with high numbers of tumor-infiltrating
CD3/CD56þ NK cells (33) that recognize antigens in the absence of
MHCmolecules via activatory receptors belonging to the C-type lectin
family (34–36).
Herein, the efficacy of adoptively transferred, ex vivo–stimulated
NK cells in patients with advanced NSCLC was studied. Because the
OS of patients with mHsp70-positive tumors is generally lower than
that of their mHsp70-negative counterparts (37), only patients with
mHsp70-positive tumors were randomized into the study. As viable
tumor cells with an mHsp70-positive phenotype actively release
exosome-associated Hsp70 into the extracellular milieu (38), the
mHsp70 status of tumors was determined in the blood by the lipHsp70
ELISA (17). A limitation of the blood-based assay is that it is unable to
distinguish exosomal Hsp70 derived from viable tumor cells and free
Hsp70 derived from dying tumor cells.
Previous studies revealed that patients with solid tumors fre-
quently have dysfunctional NK cells (15), and that after 4 repeated
reinfusion cycles, activated NK cells can be detected in the periph-
eral blood (13, 14). Therefore, 4 reinfusion cycles were given in the
study. Exosomal Hsp70 derived from mHsp70-positive tumor cells
in the presence of proinflammatory cytokines can attract NK cells
and stimulate their cytolytic activity, in vitro (38). This mechanism
might also be active in vivo in responding patients after adoptive
transfer of mHsp70-targeting NK cells. Together with the finding
that NK stimulation is more efficient when PBLs instead of sorted
NK cells are incubated with TKD/IL2 (unpublished observation),
we hypothesize that due to a yet undefined cross-presentation of
Hsp70-peptide, in vivo, resting NK cells become stimulated in the
body of responding patients.
All study patients with advancedmHsp70-positive NSCLC received
RCT for tumor debulking and to increase the density of damage-
associated molecular patterns (DAMP), including Hsp70 in the cir-
culation. Therapy-induced cellular stress provides critical cues for
activating the innate immune system (39), and Hsp70 released from
stressed tumor cells has been found to support antitumor immunity via
TLR4 pathway (40). In line with this hypothesis, tumor response was
associated with increased Hsp70 concentrations in the peripheral
blood after therapy which dropped below initial levels after adoptive
transfer of ex vivo TKD/IL2-stimulated NK cells.
The repeated treatments with autologous NK cells every 2 to
6 weeks directly after RCT were well tolerated, and no severe
toxicities and no differences in QoL were observed in both arms
of the open study. Due to ethical restrictions, only patients of the
INT, but not of the CTRL, group received leukapheresis. The
absolute number and percentage of CD3/CD56þ NK cells grad-
ually increased in the peripheral blood of patients from the first to
the fourth stimulation cycle, thereby indicating that the ex vivo
stimulation with TKD/IL2 concomitant with the release of DAMPs
and Hsp70 might support NK-cell proliferation, in vivo. An
increased cell surface density of activating receptors including
CD94/NKG2C which serves as a surrogate marker for the cytolytic
activity of NK cells against mHsp70-positive tumor cells (35, 36)
was shown in all reinfused cellular products.
Compared with the CTRL arm in which only 2 patients showed
clinical responses (PR, SD) and 5 patients had PD, the clinical outcome
for patients in the INT armwasmarkedly better, most likely due to the
adoptive transfer of activatedNKcells: one patient had aCR, 1 patient a
PR, 2 patients had SD, and only 1 patient experienced PD at the last
documented visit 18 months after randomization. Because tumor
progression was associated with a drastic drop in the ratio of NK
cells, it was assumed that NK cells are involved in tumor control.
Historically, RCT was considered as being immunosuppressive
because of large radiation fields that included substantial volumes of
the blood and bone marrow (41). However, advances in radiotherapy
have minimized normal tissue and immune cell damage, as a result of
which major parts of the bone marrow are spared and immunosup-
pression reduced. In preclinical models and in some clinical settings,
RCT has been shown to induce immunogenic tumor cell death which
in turn can elicit abscopal effects which can support the development
of protective antitumor immunity and thereby improve clinical
outcome (42–44). In the present study, RCT did not significantly alter
the immune cell composition in responders of the INT and CTRL
arms. Preclinical studies are ongoing to determine whether hypofrac-
tionated radiation regimens might lead to a greater enhancement of
mHsp70 release which correlates with an enhanced immunity.
As extracellular Hsp70 has previously been shown to predict
the mHsp70 status in patients with NSCLC, mHsp70 positivity
of the patient’s tumor at diagnosis was confirmed by elevated
exosomal Hsp70 concentrations (45). Because only patients who
were progression free after RCT were included into the study, it was
expected that extracellular Hsp70 levels after RCT are increased as a
sign of tumor cell killing. As predicted, Hsp70 concentrations in the
blood increased in all responders. The presence of extracellular
Hsp70 derived from stressed tumor cells may also drive antitumor
immune responses (40). In the presence of proinflammatory cyto-
kines, Hsp70 cannot only attract NK cells but also stimulate their
cytolytic activity (38). Patients who did not show an increase in
extracellular Hsp70 after RCT showed neither an immune nor
antitumor response.
In order to study the immunologic effects induced by RCT and
NK-cell therapy in more detail, the composition of major lympho-
cyte subpopulations during the whole clinical course was assessed.
Interestingly, the improved clinical outcomes (estimated PFS) for
patients in the INT group were associated with an increased
prevalence of NK cells and were most likely mediated by activated
NK cells and not by CD8þ cytotoxic T cells. In contrast, clinical
responses in the 2 patients of the CTRL group were associated with
an increased prevalence of CD8þ cytotoxic T cells, with the per-
centage of NK cells remaining low throughout the whole course
of study. In an upcoming trial, it remains to be determined whether
a combinatorial therapy consisting of RCT, NK cells, and immune
checkpoint inhibitors might further improve the outcome, as
previously shown in preclinical models (46) and a case study (18).
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